Less invasive heart valve replacement put to the test against Open-Heart surgery
NCT ID NCT07413965
First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This study compares two standard procedures—minimally invasive TAVR and open-heart surgery (SAVR)—for replacing a diseased aortic valve in people with a bicuspid aortic valve. About 1,200 participants aged 50 and older with severe aortic stenosis will be randomly assigned to one of the two procedures. The goal is to see which approach is safer and more effective in the long run.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Transcatheter Aortic Valve Replacement (TAVR) and Surgical Aortic Valve Replacement (SAVR)
- What this could lead to
- If successful, this could show that a less invasive TAVR procedure is as safe and effective as open-heart surgery for people with bicuspid aortic valves, guiding better treatment choices.
- What could go wrong
- This is a large trial but has not started recruiting yet. Results may not apply to all patients, and TAVR may carry different risks (like stroke or need for reintervention) compared to surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 1,200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
May 2040
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. 50 years of age or older at time of consent 2. Severe AS deemed suitable for a bioprosthesis by a local heart team (unsuitable or patient declined a mechanical valve or Ross procedure, following demonstration of evidence-based shared decision making with a validated decision-aid(1) 3. Gated contrast CT available and suitable for core laboratory analysis; 4. BAV anatomy confirmed by CT core laboratory analysis Exclusion Criteria: 1. Recent cardiovascular intervention within 30 days prior to randomization. 2. Presence of an existing TAVR or SAVR device 3. Pregnancy or lactation 4. Extreme or prohibitive TAVR or SAVR risk, adjudicated by Patient Selection Committee (PSC) Review 5. Active enrollment in another investigational study 6. Disproportionate TAVR vs SAVR risk, as adjudicated by the patient selection committee 7. Associated aortopathy (AA≥45mm by maximal cross-sectional dimension, as confirmed by CT core laboratory analysis, or AA\<45mm but site plan for surgery of the aorta in the event of randomization to surgery 8. Site plan for treatment of concomitant non-coronary cardiovascular disease in the event of randomization to surgery (for instance, concomitant valve surgery, septal defect or coarctation repair, aorta or root replacement or repair) 9. In the presence of coronary artery disease deemed necessary for revascularization in the event of randomization to SAVR or TAVR, Syntax score ≥ 32 or deemed unsuitable for PCI, or deemed unsuitable for coronary artery bypass grafting (CABG) 10. Plan to use any device other than commercially approved Edwards balloon expandable or Medtronic self-expanding TAVR 11. Leukopenia (WBC \< 3000 cells/µL), anemia (Hgb \< 8 g/dL), Thrombocytopenia (Plt \< 50,000 cells/µL) on latest available labs within 30 days prior to randomization 12. Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation, or mechanical heart assistance within 30 days prior to randomization 13. LVEF \< 25% within 90 days prior to randomization 14. Stroke or transient ischemic attack (TIA) within 90 days prior to randomization 15. Renal insufficiency (eGFR \< 30 ml/min per the Cockcroft-Gault formula) 16. Severe lung disease (FEV1 \< 50% predicted), unresolved prior to randomization 17. History of liver disease defined as MELD Score ≥ 10 or Child-Pugh Class B or C 18. Unable to complete the KCCQ due cognitive impairment or other medical condition
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bicuspid aortic valve disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.